- Report
- December 2024
- 150 Pages
Global
From €5274EUR$5,950USD£4,585GBP
- Report
- February 2025
- 200 Pages
Global
From €3980EUR$4,490USD£3,460GBP
- Report
- June 2025
- 400 Pages
Global
From €4387EUR$4,949USD£3,814GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1773EUR$2,000USD£1,541GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2472EUR$2,789USD£2,149GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2472EUR$2,789USD£2,149GBP
- Report
- May 2024
- 139 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- May 2024
- 135 Pages
Global
From €5761EUR$6,499USD£5,008GBP
- Report
- February 2024
- 168 Pages
Global
From €7047EUR$7,950USD£6,126GBP
- Report
- July 2023
- 135 Pages
Global
From €6648EUR$7,500USD£5,779GBP
- Report
- September 2022
- 152 Pages
Global
From €6648EUR$7,500USD£5,779GBP
Vivitrol is a brand name for the injectable form of naltrexone, an opioid antagonist used to treat addiction disorders. It is used to treat alcohol and opioid dependence, and is administered once a month. Vivitrol works by blocking the effects of opioids, reducing cravings and preventing relapse. It is also used to treat opioid overdose. Vivitrol is an alternative to daily oral medications, and is often used in combination with counseling and other forms of therapy.
Vivitrol is marketed by Alkermes, a biopharmaceutical company based in Dublin, Ireland. Other companies in the market include Indivior, a British pharmaceutical company, and Orexo, a Swedish pharmaceutical company. Show Less Read more